CD7、CD19等跨髓系抗原分子在AML中的研究进展
Progress of Myeloid-Associated Antigens Such as CD7 and CD19 in AML
摘要: 【目的】急性髓系白血病(Acute myeloid leukemia, AML)是血液系统中恶性克隆程度极高的一类疾病，是我国成人白血病最常见的类型，因其预后异质性较高，缓解率及生存期不理想，需更为详细的预后危险分层以指导临床治疗，故研究跨髓系抗原分子在AML中的表达具有重大意义。【方法】本文章基于流式细胞术在白血病免疫分型中的应用，根据相关文献报道选取CD7、CD19、CD56及CD10在内的跨髓系抗原分子，结合国内外报道分析表达特征和预后意义。【结果】上述跨髓系抗原分子在AML患者中存在异常表达，其表达特征与预后存在显著关联，可作为评估预后的因素之一。CD19阳性为预后良好的标志物之一，CD7和CD56的异常表达多与预后不良密切相关，CD10对于AML的影响仍待更多探索。【结论】CD7、CD19、CD56及CD10可以为AML危险分层提供更精确的依据，有利于临床医生进行个体化治疗。
Abstract: [Purpose] Acute myeloid leukemia (AML) is a highly malignant clonal disorder of hematopoietic stem cells with marked prognostic heterogeneity. Accurate risk stratification is essential to optimize treatment strategies. [Method] This article is based on the application of flow cytometry in the immunophenotyping of leukemia. Based on relevant literature, it selects myeloid-associated antigen molecules including CD7, CD19, CD56, and CD10, and analyzes their expression characteristics and prognostic significance in conjunction with domestic and international reports. [Result] The aforementioned myeloid-associated antigen molecules exhibit abnormal expression in AML patients, and their expression characteristics are significantly associated with prognosis, serving as one of the factors for evaluating prognosis. CD19 positivity is one of the markers for good prognosis, while abnormal expression of CD7 and CD56 is often closely related to poor prognosis. The impact of CD10 on AML still requires further investigation. [Conclusion] CD7, CD19, CD56, and CD10 may serve as valuable markers for AML risk stratification and individualized therapy, facilitating individualized treatment by clinicians.
文章引用：刘倩, 沈燕. CD7、CD19等跨髓系抗原分子在AML中的研究进展[J]. 临床医学进展, 2025, 15(12): 1531-1539. https://doi.org/10.12677/acm.2025.15123561

参考文献

[1] Schlenk, R.F. (2023) Acute Myeloid Leukemia: Introduction to a Series Highlighting Progress and Ongoing Challenges. Haematologica, 108, 306-307. [Google Scholar] [CrossRef] [PubMed]
[2] Horibata, S., Gui, G., Lack, J., DeStefano, C.B., Gottesman, M.M. and Hourigan, C.S. (2019) Heterogeneity in Refractory Acute Myeloid Leukemia. Proceedings of the National Academy of Sciences, 116, 10494-10503. [Google Scholar] [CrossRef] [PubMed]
[3] Kaufman, R.E., Haynes, B.F., Sempowski, G.D. and Lee, D.M. (1999) Structure and Function of the CD7 Molecule. Critical Reviews in Immunology, 19, 18. [Google Scholar] [CrossRef] 
[4] Liu, J., Zhang, Y., Guo, R., Zhao, Y., Sun, R., Guo, S., et al. (2023) Targeted CD7 CAR T-Cells for Treatment of T-Lymphocyte Leukemia and Lymphoma and Acute Myeloid Leukemia: Recent Advances. Frontiers in Immunology, 14, Article 1170968. [Google Scholar] [CrossRef] [PubMed]
[5] Gomes-Silva, D., Atilla, E., Atilla, P.A., Mo, F., Tashiro, H., Srinivasan, M., et al. (2019) CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Molecular Therapy, 27, 272-280. [Google Scholar] [CrossRef] [PubMed]
[6] 胡超杰, 邬志伟, 李庆, 等. CD7阳性急性髓系白血病患者细胞遗传学及临床特征分析[J]. 白血病·淋巴瘤, 2018, 27(9): 513-516.
[7] Raza, H., Fatima, M., Noor, T., Umer, S., Imran, A. and Malik, N.A. (2022) The Frequency of Aberrant CD7 Antigen Expression in Acute Myeloid Leukaemia Patients. Cureus, 14, e29317. [Google Scholar] [CrossRef] [PubMed]
[8] 季素芳;丁韧烨;郭晓珺. 不同剂量阿糖胞苷的DA方案治疗CD7抗原阳性急性髓系白血病疗效分析[J]. 实用肿瘤杂志, 2009, 24(4): 378-380.
[9] 孟君霞, 武永强, 唐广, 等. CD7抗原表达与急性髓系白血病临床特征、细胞遗传学特点及预后的关系[J]. 新乡医学院学报, 2016, 33(6): 508-510+514.
[10] 方汉波, 王晔恺, 周吉航, 等. CD7、CD56共表达对急性髓系白血病侵袭性的影响[J]. 放射免疫学杂志, 2012, 25(2): 197-199.
[11] Bai, Y., Sun, X., Li, M., Niu, X., Cao, W., Niu, J., et al. (2024) CD7-Positive Leukemic Blasts with DNMT3A Mutations Predict Poor Prognosis in Patients with Acute Myeloid Leukemia. Frontiers in Oncology, 14, Article 1342998. [Google Scholar] [CrossRef] [PubMed]
[12] Zhu, M.Y., Zhu, Y., Chen, R.R., et al. (2020) CD7 Expression and Its Prognostic Significance in Acute Myeloid Leukemia Patients with Wild-Type or Mutant CEBPA. Chinese Journal of Hematology, 41, 100-105.
[13] Kaheled, O., Aref, S., El Menshawy, N., Aref, M. and Ayed, M. (2023) Frequency and Prognostic Impact of Aberrant Antigens Expression among Egyptian Adult Acute Leukemia. Asian Pacific Journal of Cancer Prevention, 24, 4301-4307. [Google Scholar] [CrossRef] [PubMed]
[14] Hoch, R.E.E., Cóser, V.M., Santos, I.S. and de Souza, A.P.D. (2021) Lymphoid Markers Predict Prognosis of Pediatric and Adolescent Acute Myeloid Leukemia. Leukemia Research, 107, Article 106603. [Google Scholar] [CrossRef] [PubMed]
[15] Lu, P., Zhang, X., Yang, J., Li, J., Qiu, L., Gong, M., et al. (2025) Nanobody-Based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia. Blood, 145, 1022-1033. [Google Scholar] [CrossRef] [PubMed]
[16] Yamada, S., Kaneko, M.K., Sayama, Y., Asano, T., Sano, M., Yanaka, M., et al. (2020) Development of Novel Mouse Monoclonal Antibodies against Human CD19. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 39, 45-50. [Google Scholar] [CrossRef] [PubMed]
[17] Fujimoto, M. and Sato, S. (2007) B Cell Signaling and Autoimmune Diseases: CD19/CD22 Loop as a B Cell Signaling Device to Regulate the Balance of Autoimmunity. Journal of Dermatological Science, 46, 1-9. [Google Scholar] [CrossRef] [PubMed]
[18] Ma, G., Wang, Y., Ahmed, T., Zaslav, A., Hogan, L., Avila, C., et al. (2018) Anti-CD19 Chimeric Antigen Receptor Targeting of CD19 + Acute Myeloid Leukemia. Leukemia Research Reports, 9, 42-44. [Google Scholar] [CrossRef] [PubMed]
[19] 王晚霞, 李敬东. 淋系抗原表达对急性髓系白血病预后的价值[J]. 现代肿瘤医学, 2022, 30(9): 1667-1671.
[20] Zhang, X., Wang, L., Qiao, J., Wang, S., Wang, L., Liu, L., et al. (2025) Anti-CD19 CAR-T Cell Therapy in Relapsed/Refractory T(8;21) Acute Myeloid Leukemia with Aberrant CD19 Expression. Frontiers in Immunology, 16, Article 1617589. [Google Scholar] [CrossRef] [PubMed]
[21] Danylesko, I., Shem-Tov, N., Yerushalmi, R., Jacoby, E., Toren, A., Shouval, R., et al. (2024) Point of Care CD19 Chimeric Antigen Receptor (CAR) T-Cells for Relapsed/Refractory Acute Myeloid Leukemia (AML) with Aberrant CD19 Antigen Expression. Current Research in Translational Medicine, 72, Article 103471. [Google Scholar] [CrossRef] [PubMed]
[22] Kita, K., Nakase, K., Miwa, H., Masuya, M., Nishii, K., Morita, N., et al. (1992) Phenotypical Characteristics of Acute Myelocytic Leukemia Associated with the T (8; 21) (q22; q22) Chromosomal Abnormality: Frequent Expression of Immature B-Cell Antigen CD19 Together with Stem Cell Antigen CD34. Blood, 80, 470-477. [Google Scholar] [CrossRef] 
[23] 胡忠利, 张凤, 黄保军, 等. CD19、CD56在急性髓系白血病RUNX1-RUNX1T1+突变患者中的表达及其临床意义[J]. 中国实验血液学杂志, 2018, 26(3): 727-732.
[24] Plesa, A., Labussière-Wallet, H., Hayette, S., Salles, G., Thomas, X. and Sujobert, P. (2019) Efficiency of Blinatumomab in a T (8; 21) Acute Myeloid Leukemia Expressing CD19. Haematologica, 104, e487-e488. [Google Scholar] [CrossRef] [PubMed]
[25] Sakamoto, K., Shiba, N., Deguchi, T., Kiyokawa, N., Hashii, Y., Moriya-Saito, A., et al. (2019) Negative CD19 Expression Is Associated with Inferior Relapse-Free Survival in Children with RUNX1-Runx1t1-Positive Acute Myeloid Leukaemia: Results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 Study. British Journal of Haematology, 187, 372-376. [Google Scholar] [CrossRef] [PubMed]
[26] Iriyama, N., Hatta, Y., Takeuchi, J., Ogawa, Y., Ohtake, S., Sakura, T., et al. (2013) CD56 Expression Is an Independent Prognostic Factor for Relapse in Acute Myeloid Leukemia with T(8;21). Leukemia Research, 37, 1021-1026. [Google Scholar] [CrossRef] [PubMed]
[27] Jahedi, M., Shamsasenjan, K., Sanaat, Z., et al. (2014) Aberrant Phenotype in Iranian Patients with Acute Myeloid Leukemia. Advanced Pharmaceutical Bulletin, 4, 175-180.
[28] Wang, B., Yang, B., Ling, Y., Zhang, J., Hua, X., Gu, W., et al. (2021) Role of CD19 and Specific KIT-D816 on Risk Stratification Refinement in T (8; 21) Acute Myeloid Leukemia Induced with Different Cytarabine Intensities. Cancer Medicine, 10, 1091-1102. [Google Scholar] [CrossRef] [PubMed]
[29] Picard, L.K., Claus, M., Fasbender, F. and Watzl, C. (2022) Human NK Cells Responses Are Enhanced by CD56 Engagement. European Journal of Immunology, 52, 1441-1451. [Google Scholar] [CrossRef] [PubMed]
[30] Liang, T., Peng, Z., Li, C., Huang, J., Wang, H., Bu, C., et al. (2022) Evaluating the Prognostic Value of CD56 in Pediatric Acute Myeloid Leukemia. BMC Cancer, 22, Article No. 1339. [Google Scholar] [CrossRef] [PubMed]
[31] Alegretti, A.P., Bittar, C.M., Bittencourt, R., Piccoli, A.K., Schneider, L., Silla, L.M., et al. (2011) The Expression of CD56 Antigen Is Associated with Poor Prognosis in Patients with Acute Myeloid Leukemia. Revista Brasileira de Hematologia e Hemoterapia, 33, 202-206. [Google Scholar] [CrossRef] [PubMed]
[32] Gattenloehner, S., Chuvpilo, S., Langebrake, C., Reinhardt, D., Müller-Hermelink, H., Serfling, E., et al. (2007) Novel RUNX1 Isoforms Determine the Fate of Acute Myeloid Leukemia Cells by Controlling CD56 Expression. Blood, 110, 2027-2033. [Google Scholar] [CrossRef] [PubMed]
[33] Shikami, M., Miwa, H., Nishii, K., Takahashi, T., Shiku, H., Tsutani, H., et al. (1999) Myeloid Differentiation Antigen and Cytokine Receptor Expression on Acute Myelocytic Leukaemia Cells with T (16; 21) (p11; q22): Frequent Expression of CD56 and Interleukin-2 Receptor α Chain. British Journal of Haematology, 105, 711-719. [Google Scholar] [CrossRef] [PubMed]
[34] Jekarl, D.W., Kim, M., Lim, J., Kim, Y., Han, K., Lee, A., et al. (2010) CD56 Antigen Expression and Hemophagocytosis of Leukemic Cells in Acute Myeloid Leukemia with T (16; 21) (p11; q22). International Journal of Hematology, 92, 306-313. [Google Scholar] [CrossRef] [PubMed]
[35] Chang, H., Salma, F., Yi, Q., Patterson, B., Brien, B. and Minden, M.D. (2004) Prognostic Relevance of Immunophenotyping in 379 Patients with Acute Myeloid Leukemia. Leukemia Research, 28, 43-48. [Google Scholar] [CrossRef] [PubMed]
[36] Kushwaha, A.C., Mrunalini, B., Malhotra, P. and Roy Choudhury, S. (2024) CD56-Targeted in Vivo Genetic Engineering of Natural Killer Cells Mediates Immunotherapy for Acute Myeloid Leukemia. Nanoscale, 16, 19743-19755. [Google Scholar] [CrossRef] [PubMed]
[37] Cuneo, A., Michaux, J.L., Ferrant, A., Van Hove, L., Bosly, A., Stul, M., et al. (1992) Correlation of Cytogenetic Patterns and Clinicobiological Features in Adult Acute Myeloid Leukemia Expressing Lymphoid Markers. Blood, 79, 720-727. [Google Scholar] [CrossRef] 
[38] Wang, W. and Xu, Y. (2020) Analysis of Immunophenotypes and Expressions of Non-Myeloid Antigens in Acute Myeloid Leukemia. Journal of Southern Medical University, 40, 1639-1644.
[39] Legrand, O., Perrot, J.Y., Baudard, M., Cordier, A., Lautier, R., Simonin, G., et al. (2000) The Immunophenotype of 177 Adults with Acute Myeloid Leukemia: Proposal of a Prognostic Score. Blood, 96, 870-877. [Google Scholar] [CrossRef] 

为你推荐